Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Cost of Revenue: 2019-2024

Historic Cost of Revenue for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Dec 2024 value amounting to $150.9 million.

  • Maravai Lifesciences Holdings' Cost of Revenue fell 2.22% to $36.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $151.9 million, marking a year-over-year increase of 2.07%. This contributed to the annual value of $150.9 million for FY2024, which is 1.43% up from last year.
  • Latest data reveals that Maravai Lifesciences Holdings reported Cost of Revenue of $150.9 million as of FY2024, which was up 1.43% from $148.7 million recorded in FY2023.
  • Maravai Lifesciences Holdings' 5-year Cost of Revenue high stood at $169.0 million for FY2022, and its period low was $79.6 million during FY2020.
  • Moreover, its 3-year median value for Cost of Revenue was $150.9 million (2024), whereas its average is $156.2 million.
  • Per our database at Business Quant, Maravai Lifesciences Holdings' Cost of Revenue surged by 76.48% in 2021 and then fell by 11.96% in 2023.
  • Maravai Lifesciences Holdings' Cost of Revenue (Yearly) stood at $79.6 million in 2020, then skyrocketed by 76.48% to $140.6 million in 2021, then grew by 20.20% to $169.0 million in 2022, then decreased by 11.96% to $148.7 million in 2023, then climbed by 1.43% to $150.9 million in 2024.